secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001104659-23-035822
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio receives FDA 510(k) clearance for OviTex PRS Long-Term Resorbable
--------------------------------------------------------------------------

- FDA granted 510(k) clearance on March 23, 2023 for OviTex PRS Long-Term Resorbable.
- Product reinforces soft tissue in plastic and reconstructive surgery where weakness exists.
- Complements existing OviTex PRS Permanent and Short-Term Resorbable configurations.
- Design features bi-directional stretch and a fully resorbable long-term polymer.
- CEO Antony Koblish states it expands clinical utility and demonstrates tunable design capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923035822/0001104659-23-035822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923035822/tm239776d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-035822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer